There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.

There Are No Bad Anticancer Agents , Only Bad Clinical Trial

Unfortunately, the vast majority (90%) of new anticancer agents designed in the laboratory never make it into routine clinical use. The hypothesis of this lecture is that many new agents fail in the clinic because the appropriate clinical trial(s) that could exploit the attributes of the new agent are not performed. An appreciation that both bench and clinical investigations are difficult endea...

How Cancer Cells Evade Chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture1

Tumor biology and clinical trials: the Richard and Hinda Rosenthal Foundation Award Lecture.

Laboratory research is often described as basic and clinical research, prognostic or empirical. In this address, the point is made that research may be clinical or laboratory. Good clinical research may give important biological answers. Breast cancer clinical trials are decribed in terms of their biological interpretation. A list of significant biological questions that need answering are pres...

Tumor Biology and Clinical Trials: The Richard and Hinda Rosenthal Foundation Award Lecture1

Laboratory research is often described as basic and clinical research, prognostic or empirical. In this address, the point is made that research may be clinical or labora tory. Good clinical research may give important biological answers. Breast cancer clinical trials are described in terms of their biological interpretation. A list of significant biolog ical questions that need answering are p...

Basic principles and applications of monoclonal antibodies in the management of carcinomas: the Richard and Hinda Rosenthal Foundation award lecture.

The advent of hybridoma technology in 1975 (1) represented a quantum leap in the field of tumor immunology. For the first time, B-lymphocytes from immunized hosts could be immor talized by means of fusion with drug selected non-immunoglobulin secretor murine myeloma cells. These fused cell products could then be cloned and propagated indefinitely. The super natant fluids of cultures from litera...